{
    "clinical_study": {
        "@rank": "23321", 
        "acronym": "ESCAPE", 
        "biospec_descr": {
            "textblock": "Bacterial cultures"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This project aims at investigating the duration of human fecal carriage of bacteria\n      harboring plasmid-borne resistance genes expressing Extended Spectrum beta-lactamases\n      (ESBL), risk factors for infections with such bacteria and persistence, mobility and spread\n      of ESBL in the environment and within households. It also aims to compare different methods\n      of detecting ESBL carriage and treat patients with urinary tract infection caused by these\n      bacteria."
        }, 
        "brief_title": "Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients", 
        "condition": "Urinary Tract Infection", 
        "condition_browse": {
            "mesh_term": "Urinary Tract Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients >=18 of age with a urine culture yielding E. coli or K. pneumoniae >10.000\n             colony forming units/mL.\n\n        Exclusion Criteria:\n\n          -  Patients who have lived in Norway for <1 year\n\n          -  Patients who are unable to answer a questionaire\n\n          -  Patients who have been infected with an ESBL producing bacteria before\n\n          -  Patients who have been admitted to a hospital or a long term care facility for >24\n             hours during the past 31 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients living in Eastern Norway who have an urine submitted for culturing to the\n        Department of Medical Microbiology, Vestre Viken Hospital Trust, which covers an area of\n        about 450.000 inhabitants.\n\n        All patients with an bacteria producing ESBL were eligible while patients without ESBL\n        producing bacteria were randomly sampled."
            }
        }, 
        "enrollment": {
            "#text": "760", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838213", 
            "org_study_id": "REK S-08901b"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Urinary tract infection", 
            "ESBL", 
            "treatment", 
            "carriage", 
            "risk factors"
        ], 
        "lastchanged_date": "April 22, 2013", 
        "number_of_groups": "1", 
        "official_title": "Extended Spectrum Beta-lactamases - Treatment, Carriage, Environmental Dissemination And Population Epidemiology", 
        "other_outcome": {
            "description": "Culture results from patient fecal samples will be collected up to 3 years after urinary tract infection and carriage of ESBL producing bacteria will be examined.", 
            "measure": "Carriage of ESBL producing bacteria", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "overall_official": {
            "affiliation": "Vestre Viken Hospital Trust", 
            "last_name": "P\u00e5l A Jenum, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Norway: South Eastern Health Authority", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients included in the study with urinary tract infection (UTI) and treated with an antimicrobial agent will be followed for 14 days and further prescriptions of antimicrobials normally used for treatment of UTI will be considered treatment failures.", 
            "measure": "Treatment failure", 
            "safety_issue": "No", 
            "time_frame": "14 days after initiation of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838213"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A patient form will be filled in. Data about cessation of symptoms of urinary tract infection will be recorded.", 
            "measure": "Subjective outcome", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "source": "Vestre Viken Hospital Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vestre Viken Hospital Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}